14T158: Abstracts: SLE – Treatment II: Nonrenal (2485–2490)

Presenting Author(s)

• CA

  Cristina Arriens, MD, MS

  Oklahoma Medical Research Foundation
  Oklahoma City, OK, United States

  Disclosure information not submitted.
• 

  April Jorge, MD

  Massachusetts General Hospital
  Boston, MA, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose
• JM

  Joan Merrill, MD

  Oklahoma Medical Research Foundation
  Oklahoma City 73104, OK, United States

  Disclosure information not submitted.
• EO

  Ewa Olech, MD (she/her/hers)

  Rheumatology Consultants, PLLC
  Las Vegas, NV, United States

  Disclosure information not submitted.
• NS

  Nan Shen, MD, PhD

  Shanghai Jiang Tong University School of Medicine
  Shanghai, Shanghai, China

  Disclosure(s): No financial relationships with ineligible companies to disclose
• JY

  Junna Ye, MD

  Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
  Shanghai, Shanghai, China

  Disclosure information not submitted.

Abstract oral session.

Non-CME

Presentations:

• 2:00 PM - 2:10 PM PT

  Comparative Risk of Serious Psychiatric Events with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus
  

  Presenting Author: April Jorge, MD – Massachusetts General Hospital
• 2:10 PM - 2:15 PM PT

  Q&A
  
• 2:15 PM - 2:25 PM PT

  Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores?
  

  Presenting Author: Ewa Olech, MD (she/her/hers) – Rheumatology Consultants, PLLC
• 2:25 PM - 2:30 PM PT

  Q&A
  
• 2:30 PM - 2:40 PM PT

  Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity
  

  Presenting Author: Nan Shen, MD, PhD – Shanghai Jiang Tong University School of Medicine
• 2:40 PM - 2:45 PM PT

  Q&A
  
• 2:45 PM - 2:55 PM PT

  Efficacy and Safety of ABBV-599 High Dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: A Phase 2, Double-blind, Placebo-controlled Trial
  

  Presenting Author: Joan Merrill, MD – Oklahoma Medical Research Foundation
• 2:55 PM - 3:00 PM PT

  Q&A
  
• 3:00 PM - 3:10 PM PT

  Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Achievement and Sustained Response with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE
  

  Presenting Author: Cristina Arriens, MD, MS – Oklahoma Medical Research Foundation
• 3:10 PM - 3:15 PM PT

  Q&A
  
• 3:15 PM - 3:25 PM PT

  Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial
  

  Presenting Author: Junna Ye, MD – Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
• 3:25 PM - 3:30 PM PT

  Q&A